Course of Preexisting Migraine Following Spontaneous Subarachnoid Hemorrhage

José Manuel Valdueza 1,*, Jens Peter Dreier 2,3,4,5,6, Johannes Woitzik 2,7,8, Christian Dohmen 9, Oliver Sakowitz 10, Johannes Platz 11, Stefanie Leistner-Glaess 3 and Victoria Dorothea Witt 12

1 Neurological Center, Segeberger Kliniken, Bad Segeberg, Germany, 2 Center for Stroke Research Berlin, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universitäts zu Berlin, Berlin Institute of Health, Berlin, Germany, 3 Department of Neurology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universitäts zu Berlin, Berlin Institute of Health, Berlin, Germany, 4 Experimental Neurology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universitäts zu Berlin, Berlin Institute of Health, Berlin, Germany, 5 Bernstein Center for Computational Neuroscience Berlin, Berlin, Germany, 6 Einstein Center for Neurosciences Berlin, Berlin, Germany, 7 Department of Neurosurgery, Charité–Universitätsmedizin Berlin, Berlin, Germany, 8 Department of Neurosurgery, Evangelisches Krankenhaus, Carl-von-Ossietzky University, Oldenburg, Germany, 9 Department of Neurology, LVR-Hospital Bonn, Bonn, Germany, 10 Department of Neurosurgery, Neurochirurgische Universitätsklinik, Heidelberg, Germany, 11 Department of Neurosurgery, Heart-Neuro-Center Bodensee, Münsterlingen, Switzerland, 12 Psychiatric Center Rickling, Rickling, Germany

Background: Our objective was to observe the course of preexisting migraine following subarachnoid hemorrhage (SAH) in patients with and without craniotomy.

Methods: We designed an exploratory analysis and hypothesis-generating study of prospectively collected data starting by recruiting patients suffering from SAH with the Hunt and Hess scale score of ≤4. Out of 994 cases, we identified 46 patients with preexisting active migraine defined by at least four attacks in the year before SAH. According to the treatment, we subdivided the patients into two groups: the first group included patients with surgical aneurysm clipping with transection of the middle meningeal artery (MMA) and accompanying trigeminal nerve branches and the second group included patients with endovascular aneurysm coilning or without any interventional treatment. During the follow-up, we recorded the course of migraine frequency, duration, intensity, and character.

Results: For both groups (craniotomy n = 31, without craniotomy n = 15), a significant improvement regarding the preexisting migraine during a mean follow-up of 46 months (min. 12 months, max. 114 months) was seen regarding complete remission or at least >50% reduction in migraine attacks (p < 0.001 and p = 0.01). On comparing the groups, this effect was significantly more pronounced in patients with craniotomy (for no recurrence of migraine: p = 0.049). After craniotomy, 77.4% of the patients had no further attacks of migraine headache and 19.4% showed a reduction of >50%, while only 2.2% did not report any relevant change. In the non-surgical group, 46.7% had no further migraine attacks, 20% had a reduction of >50%, while no change was noted in 33.3%.
INTRODUCTION

Migraine is generally assumed as a trigeminovascular headache syndrome. The current models describe vasoactive peptides such as calcitonin gene-related peptide (CGRP), substance P, vasoactive intestinal polypeptide (VIP), and pituitary adenylate cyclase-activating polypeptide (PACAP) being released in the trigeminal ganglion (1). According to these models, they reach vessels and the dura mater via efferent axons and lead to neurogenic inflammation with extravasation of plasma, upregulation of pain sensitivity, vasodilatation, stimulation of nociceptors, and activation of the trigeminal pain system.

Historically, Harold Wolff focused on the role of extracranial vasodilation in the pathogenesis of migraine headaches (2). However, most studies have concluded that extracranial vasodilation, if present at all, is an epiphenomenon rather than a key mechanism during a migraine attack and thus is no target for antimigraine drugs. For example, the potent vasodilator nitroglycerine was not effective in inducing an immediate migraine attack, whereas it immediately dilated the extracranial middle meningeal artery (MMA) (3, 4). Pain occurred only hours later when vasodilation had already subsided. Furthermore, the potent vasodilator VIP failed to induce a headache in patients with migraine (5) despite the fact that in vitro it dilates the human MMA (6).

Nonetheless, some more recently published studies support the notion that the MMA may be involved in the pathogenesis of migraine headaches through vasodilation and upregulated nociception. For instance, in 2010, Asghar et al. performed a double-blind, randomized, placebo-controlled, crossover study that included 18 healthy volunteers using magnetic resonance angiography (MRA). They found that CGRP caused the extracranial part of the MMA to dilate by 5.7% after correction for placebo-induced dilation without effect on the diameter of the main stem of the middle cerebral artery (MCA). Sumatriptan led to a vasoconstriction of the MMA in subjects not treated before with CGRP by 15% whereas the vasoconstriction of the MCA was only 5.3% (7). The in vivo studies in rats even showed that CGRP led to diameter increases of the MMA by more than 50% (8). Direct ictal MMA measurements are rare. However, in 2009, Nagata et al. performed MRA 2 h after the onset of a spontaneous migraine attack in a 42-year-old woman. The authors reported a diameter increase of up to 15% in the extracranial portion of the MMA compared to baseline (9).

There are rare observations about surgical options. In the 1930’s, Dickerson followed up on the four patients with migraine after MMA ligation, with three symptom-free (10). In a more recent study, ligation of the MMA together with the superficial temporal artery and the greater superficial petrosal nerve led to complete remission for at least 2 years in all the 10 treated patients with severe refractory migraine (11). Closure of the MMA using catheter techniques is nowadays used in the treatment of dural arteriovenous fistulas and chronic subdural hematomas (12, 13). Interestingly, seven out of nine patients with chronic subdural hematoma who suffered from “chronic headache” for at least 2 years and whose MMA was embolized were completely headache-free during a mean follow-up of 489 days (14).

The MMA is usually transected also during frontotemporal craniotomy in the surgical treatment of intracranial aneurysms. The aim of the present study was to investigate the course of preexisting migraine in patients with craniotomy following subarachnoid hemorrhage (SAH). Non-surgically treated patients with SAH without any intervention or coiling served as the control group.

METHODS

Patient Recruitment and the Study Protocol

We recruited patients with acute SAH at a large center for neurological rehabilitation (CNR) and at six university clinics participating in Co-Operative Studies on Brain Injury Depolarizations (COSBID). In total, 763 patients entered the CNR with the primary diagnosis of SAH between March 2005 and January 2015. The selection of participants was performed by a detailed headache questionnaire comprising each clinical symptom as defined in the International Headache Society (IHS) criteria for migraine (15) when the patients were admitted with the principal diagnosis and after initial treatment of SAH. In addition, the six centers of the COSBID group enrolled 231 patients with SAH between April 2005 and March 2015. Prospective inclusion criteria for COSBID have been described previously (16). To analyze the impact of SAH and its treatment on the course of migraine headache, we screened patients with a Hunt and Hess scale score of ≤4 retrospectively for a history of active migraine prior to the SAH. All research was conducted in accordance with the Declaration of Helsinki. The Institutional Review Board approved the research protocols and we obtained surrogate informed consent from all the patients.

Migraine

Migraine was diagnosed according to the criteria given in the 2nd edition of the International Classification of Headache (IHS)
Disorders (15). We defined active migraine as at least four migraine attacks within the year prior to SAH to rule out a warning leak as the harbinger of the SAH. We also screened for a history of migraine aura. The patients with only isolated aura but the absence of typical headaches were excluded.

**Subarachnoid Hemorrhage and Initial Treatment**

Subarachnoid hemorrhage (SAH) was classified clinically according to the grading scale by Hunt and Hess (17). The amount and distribution of subarachnoid blood were graded according to the Fisher scale (18). After the diagnosis of SAH, surgical clipping and/or endovascular coiling was performed within the next 24 h. Secondary treatments (both coiling and clipping) were sometimes necessary due to a lack of effectiveness. Three patients did not undergo any interventional treatment due to failure to locate the origin of the bleeding. In all cases of surgical aneurysm clipping, a frontotemporal craniotomy was done, which includes transection of the MMA and the accompanying trigeminal nerve branches during the opening of the dura mater. In cases of surgical clipping, we documented the side of trepanation for correlation with the dominant location of migraine headache.

**Study Protocol**

We selected all patients with SAH who suffered from preexisting migraine for subsequent analysis. For each patient identified with preexisting migraine, follow-up investigations (min. 12 months, max. 114 months) were performed by either a telephonic interview or an outpatient examination. In addition to the criteria for migraine and migraine aura, we collected the following data during initial and follow-up interviews: age, sex, prophylactic and acute medication prior and past SAH, location, and preferred side of headache. To address the issue of the transection of the MMA and trigeminal nerve branches, we compared patients with craniotomy and endovascular coiling or no treatment. For statistical analysis, we used the SPSS Statistics (IBM SPSS Statistics Version 20, International Business Machines Corp., New York, USA) software package. On analyzing the McNemar–Bowker test, the Wilcoxon test, and the Fisher exact test, we considered p-values of <0.05 significant. In accordance with standard prophylactic drugs, a significant reduction in migraine

---

**FIGURE 1** | Overview of patient flow (NZ, center for neurological rehabilitation; COSBID, Co-Operative Studies on Brain Injury Depolarizations).
was defined as a decrease of more than 50% compared to the attack frequency prior to SAH (19). Possible confounders such as age, medication, changes in way of living, physical and mental condition, and stress factors were enquired in the interviews.

RESULTS

From 994 cases with SAH in the CNR and COSBID group (see Figure 1 overview), we identified 60 patients who strictly met the criteria from preexisting, active migraine (CNR n = 36, COSBID n = 24). Fourteen subjects failed to participate in follow-up investigations due to rejection, missing contact data, or death and, therefore, were excluded. Accordingly, 46 patients (see Table 1) were included in subsequent analysis and statistical calculation (CNR n = 33, COSBID n = 13). Table 2 summarizes the individual demographic and clinical data. Twenty-one patients underwent surgical clipping, 12 patients endovascular coiling, and 10 patients both procedures to finally treat the aneurysm. Three patients had an angio-negative SAH. Fourteen patients had a history of migraine aura. Table 3 documents the migraine situation regarding frequency, duration, intensity, and attendant symptoms for the time before and after the occurrence of SAH.

During an observation period of 46 months (mean, range 12–114 months, SD ± 27.8), migraine attacks stopped in 31 out of 46 patients (67.4%). After craniotomy, 24 (77.4%) patients had no further attacks of migraine headache and six (19.4%) showed a reduction of >50%, while only one (2.2%) did not report any relevant change. Without craniotomy, seven patients (46.7%) had no further migraine attacks and three (20%) had a reduction >50%, but no change was noted in five (33.3%) patients. Complete remission of migraine attacks was significant in both groups, the craniotomy (p < 0.001) and the non-craniotomym group (p = 0.002, Wilcoxon test). Besides, the number of patients reporting a reduction in migraine attacks of at least >50% compared to the time prior to SAH occurred in both groups (craniotomy: p < 0.001, no-craniotomy: p = 0.001, Wilcoxon test). Following craniotomy, patients showed a significantly higher rate of reduced migraine attacks (either complete or incomplete remission, p = 0.01, two-tailed Fisher exact test) and complete remission (p = 0.049, two-tailed Fisher exact test), respectively. For the other migraine criteria, we observed a significant decrease in the duration (p < 0.001) and intensity (p < 0.001) following SAH in both groups whereas the character of pain or concomitants (e.g., photophobia or nausea) did not change significantly.

A total of 11 out of 31 patients who underwent craniotomy reported a unilateral headache and in nine of them, surgery was performed on the corresponding side. All 11 reported a complete disappearance of migraine following SAH. Twenty of the surgical patients suffered from bilateral migraine pain or reported varying lateralization of headache. Of those, 16 were free of further migraine attacks. Regarding the pre-bleeding presence of migraine with or without aura, there was no statistical difference (p = 0.17, Fisher exact test).

A total of 16 out of 46 patients (34.8%) reported other types of headaches before SAH that clearly did not meet the migraine criteria. Thirteen cases (28.3%) fulfilled the IHS criteria for tension-type headaches (TTH). In three cases (6.5%), we diagnosed unspecific headaches. After treatment, TTH and unspecific headaches increased to 32.6 and 10.9%, respectively.

To test for potential confounders, such as arterial hypertension, diabetes, consumption of alcohol and nicotine, and medication containing hormones, we compared the status before and after SAH for the 31 patients with completely suspended migraine and the 15 patients with ongoing migraine. There was no significant difference in a before-after comparison. In addition, we matched both groups referring to age, sex, migraine aura, the Hunt and Hess (grade I-IV) score, Fisher grade (grade I-IV), the occurrence of hydrocephalus, and changes in medication used for first- or second-line prophylaxis in migraine (e.g., metoprolol, propranolol, flunarizine, topiramate, valproate, tricyclic antidepressants, gabapentin, or mirtazapine). No significant difference was detected regarding age (p = 0.13, Mann–Whitney-U test) and sex (p = 1.0, Fisher exact test). The mean age was 48.9 ± 9.9 years (5 men, 26 women) in the group without migraine compared to 44.9 ± 7.4 years (3 men, 12 women) in the group with ongoing migraine. A significant difference was found only in relation to the Hunt and Hess scores, as migraine disappeared significantly more frequently in patients with higher Hunt and Hess levels (2.81 vs. 2.1, p = 0.016, Mann–Whitney test). Fisher grade (p = 0.98) and aura (p = 0.165) did not show a significant difference.

DISCUSSION

The burden of migraine is impressively reduced after acute SAH despite the treatment procedure. During a follow-up period of 12–114 months (mean ± 26.8 months), 40 out of 46 patients had a significant reduction in headache frequency, 31 even reported a complete cessation of migraine symptoms. The reduction of migraine headaches following SAH, however, occurred significantly more often in patients following craniotomy. Regarding the possible role of the MMA, this is consistent with the small studies of Dickerson (10) and Fan et al. (11). They reported a dramatic improvement in headache frequency in a long-term follow-up for up to 14 years after ligation of the MMA. Yet, the comparability with our observation is limited. In the cohort of Dickerson and Fan et al., all the patients suffered from intractable or refractory migraine, and particularly in invasive interventions, a high ratio of placebo effects may be present (20, 21). On the contrary, we designed

---

**TABLE 1 | Table of demography — patient characteristics at baseline.**

| Variables at baseline | N = 46 |
|-----------------------|--------|
| Gender women/men, n (%) | 38 (83)/8 (17) |
| Mean Age in years (SD) | 47.6 (9.3) |
| Migraine diagnosis according to IHS criteria, n (%) | 46 (100) |
| Migraine subtype without aura/with aura, n (%) | 32 (70%)/14 (30) |
| Mean length of migraine diagnosis in years (SD) | 23.9 (12.7) |
| #  | Age | Sex | Aura | Migr.Atc/Y | Dom. Side | Aneurysm localization | Hunt & Hess | Intervention (Clipping/Coiling) | Side of trepanation |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 52 | Fem | N | 24 | Bilat | MCA | 1 | Clipping/Coiling right | Right |
| 2 | 50 | Fem | N | 12 | Vary | MCA | 4 | Clipping/Coiling left | Left |
| 3 | 54 | Fem | N | 18 | Bilat | ICA | 3 | Clipping right | Right |
| 4 | 43 | Fem | N | 6 | Bilat | ACA | 2 | Clipping right | Right |
| 5 | 46 | Fem | N | 36 | Right | MCA | 4 | Clipping/Coiling right | Right |
| 6 | 47 | Fem | N | 30 | Right | MCA | 4 | Clipping bilat. | Right |
| 7 | 51 | Fem | N | 12 | Right | Multiple | 3 | Clipping/Coiling right | Right |
| 8 | 43 | Fem | N | 12 | Right | MCA | 2 | Clipping right | Right |
| 9 | 44 | Fem | N | 4 | Right | MCA | 3 | Clipping right | Right |
| 10 | 56 | Fem | Y | 24 | Right | Multiple | 4 | Clipping left | Left |
| 11 | 61 | Fem | N | 48 | Vary | MCA | 3 | Clipping/Coiling left | Left |
| 12 | 39 | Fem | N | 12 | Right | AcomA | 2 | Clipping bilat. | Left |
| 13 | 42 | Fem | N | 12 | Left | AcomA | 2 | Coiling right | No |
| 14 | 55 | Fem | Y | 42 | Vary | MCA | 3 | Coiling left | No |
| 15 | 45 | Male | N | 72 | Vary | No Ay | 1 | No intervention | No |
| 16 | 51 | Male | N | 12 | Bilat | AcomA | 2 | Coiling bilat. | No |
| 17 | 51 | Fem | N | 10 | Vary | ACA | 2 | Coiling left | No |
| 18 | 31 | Fem | N | 12 | Vary | ICA | 2 | Coiling right | No |
| 19 | 48 | Fem | Y | 12 | Right | MCA | 1 | Clipping right | Right |
| 20 | 47 | Fem | N | 4 | Bilat | AcomA | 4 | Clipping left | Left |
| 21 | 47 | Fem | N | 48 | Vary | MCA | 3 | Clipping left | Left |
| 22 | 34 | Male | Y | 18 | Vary | No Ay | 1 | No intervention | No |
| 23 | 20 | Male | N | 24 | Right | No Ay | 3 | No intervention | No |
| 24 | 47 | Fem | N | 6 | Bilat | ICA | 1 | Coiling right | No |
| 25 | 51 | Fem | N | 84 | Bilat | AcomA | 1 | Clipping left | Left |
| 26 | 55 | Fem | N | 4 | Bilat | PcomA | 3 | Coiling right | No |
| 27 | 43 | Male | N | 24 | Bilat | AcomA | 1 | Coiling left | No |
| 28 | 55 | Fem | Y | 60 | Bilat | AcomA | 2 | Coiling bilat. | No |
| 29 | 31 | Fem | N | 48 | Right | AcomA | 2 | Coiling bilat. | No |
| 30 | 52 | Fem | N | 48 | Bilat | PcomA | 4 | Clipping left | Left |
| 31 | 46 | Fem | N | 12 | Bilat | MCA | 4 | Clipping/Coiling right | Right |
| 32 | 43 | Fem | N | 24 | Bilat | MCA | 3 | Clipping/Coiling right | Right |
| 33 | 46 | Fem | N | 12 | Bilat | PcomA | 3 | Coiling bilat. | No |
| 34 | 74 | Fem | N | 12 | Bilat | AcomA | 2 | Clipping/Coiling left | Left |
| 35 | 36 | Fem | N | 12 | Left | AcomA | 2 | Clipping/Coiling right | Left |
| 36 | 56 | Fem | N | 48 | Right | MCA | 3 | Clipping right | Right |
| 37 | 46 | Fem | N | 24 | Bilat | AcomA | 2 | Clipping/Coiling right | Right |
| 38 | 48 | Fem | Y | 48 | Right | PcomA | 4 | Clipping right | Right |
| 39 | 58 | Fem | Y | 5 | Left | AcomA | 2 | Coiling bilat. | No |
| 40 | 64 | Fem | Y | 4 | Right | AcomA | 4 | Clipping right | Right |
| 41 | 44 | Fem | Y | 12 | Bilat | MCA | 2 | Clipping right | Right |
| 42 | 62 | Male | Y | 48 | Vary | PcomA | 4 | Clipping left | Left |
| 43 | 41 | Fem | Y | 12 | Vary | MCA | 2 | Clipping left | Left |
| 44 | 48 | Fem | Y | 48 | Bilat | MCA | 2 | Clipping right | Right |
| 45 | 39 | Male | Y | 72 | Bilat | ACA | 4 | Clipping left | Left |
| 46 | 49 | Male | Y | 60 | Vary | MCA | 2 | Clipping right | Right |

Age, age at the time of subarachnoid hemorrhage (SAH); y, history of migraine aura; n, no history of migraine aura; Migr.Atc/Y, Episodes the year before bleeding fulfilling the criteria of a migraine headache attack (isolated aura not included); Dom. Side, Dominant side/location of the migraine headache; Aneurysm Localization, intracranial artery of the bleeding aneurysm (ICA, internal carotid artery; MCA, middle cerebral artery; ACA, anterior cerebral artery); Side of Trepanation, if performed; PCA, posterior cerebral artery; AcomA, anterior communicating artery; PcomA, posterior communicating artery; Hunt and Hess, grade on scale, Side of Trepanation: if performed.
The fact that not only patients with migraine undergoing a craniotomy but also those undergoing endovascular embolization showed a remission from migraine after SAH suggests that other factors also may be involved. It is known that patients with an unruptured intracranial aneurysm (UIA) revealed a significantly higher migraine prevalence of 24.4% compared to 14.6% in a control group (26). Thus, migraine frequency could decrease when this risk factor is eliminated, though the pathophysiologic basis remains unclear. A potential relation between migraine and UIA has also been highlighted by a case-control study, including 51 patients with UIA and a preceding migraine in the year before surgery (27). Interestingly, migraine was significantly reduced by 74.5% 1-year after clipping, which is comparable to our craniotomy subgroup treated by clipping (77.4%).

Our results support the assumption that the elimination of an intracranial aneurysm ameliorates migraine markedly. The long average migraine history of 23.9 years in our study argues, however, that migraine is likely not related to the presence of a UIA alone.

Getting older has a great influence on the long-term course of migraine frequency and severity up to complete remission at a higher age. The overall mean age was 47.6 ± 9.3 years in our study. It seems unlikely that the dramatic improvement of migraine complaints can be solely explained by aging processes during a mean follow-up period of almost 4 years.

Newly acquired headache after SAH especially of TTH appears to be a common phenomenon. After clipping of UIA, a nonsignificant increase of TTH was reported from 37.9 to 50.6% compared to 14.6% in a control group (26). Thus, migraine frequency could decrease when this risk factor is eliminated, though the pathophysiologic basis remains unclear. A potential relation between migraine and UIA has also been highlighted by a case-control study, including 51 patients with UIA and a preceding migraine in the year before surgery (27). Interestingly, migraine was significantly reduced by 74.5% 1-year after clipping, which is comparable to our craniotomy subgroup treated by clipping (77.4%).

Several limitations must be mentioned. The demographic data and characteristics of migraine in our study are only partially consistent with the general population. In addition, our study population is not randomized, and findings lack a control group of either otherwise healthy patients with migraine or patients with SAH only. The loss to follow-up of 14 of the 60 subjects was rather high and could affect the results. Furthermore, the small sample size weakens the significance of comparing surgical vs. endovascular patients. There is also a potential for recall bias, as the pre-ictus migraine severity is determined retrospectively.

### Table 3 | Migraine situation prior to subarachnoid hemorrhage (SAH) and long-term course following SAH.

| #   | pre SAH | post SAH | Comparison | Trepanation/ Side | Outcome (BI/mRS) | Correlation |
|-----|---------|----------|------------|-------------------|-----------------|-------------|
| 1   | 24      | 0        | + (f)      | Right             | 100/1 x         |             |
| 2   | 12      | 0        | + (f)      | Left              | 100/1 x         |             |
| 3   | 18      | 0        | + (f)      | Right             | 95/1 x          |             |
| 4   | 6       | 0        | + (f)      | Right             | 100/1 x         |             |
| 5   | 36      | 0        | + (f)      | Right             | 100/1 +         |             |
| 6   | 30      | 0        | + (f)      | Right             | 100/1 +         |             |
| 7   | 12      | 0        | + (f)      | Right             | 95/2 +          |             |
| 8   | 12      | 4        | +          | Right             | 100/1 +         |             |
| 9   | 4       | 0        | + (f)      | Right             | 100/1 +         |             |
| 10  | 24      | 0        | + (f)      | Left              | 90/3 0          |             |
| 11  | 48      | 0        | + (f)      | Left              | 100/1 x         |             |
| 12  | 12      | 0        | + (f)      | Left              | 100/1 0         |             |
| 13  | 12      | 12       | -          | No                | 100/0 n         |             |
| 14  | 42      | 0        | + (f)      | No                | 100/1 n         |             |
| 15  | 72      | 48       | -          | No                | 100/0 n         |             |
| 16  | 12      | 0        | + (f)      | No                | 100/2 n         |             |
| 17  | 10      | 5        | -          | No                | 100/0 n         |             |
| 18  | 12      | 0        | + (f)      | No                | 100/0 n         |             |
| 19  | 12      | 0        | + (f)      | Left              | 75/2 +          |             |
| 20  | 4       | 1        | +          | Left              | 100/1 x         |             |
| 21  | 48      | 0        | + (f)      | Left              | 100/1 x         |             |
| 22  | 18      | 4        | +          | No                | 100/0 n         |             |
| 23  | 24      | 0        | + (f)      | No                | 100/0 n         |             |
| 24  | 6       | 3        | +          | No                | 100/1 n         |             |
| 25  | 84      | 0        | + (f)      | Left              | 100/1 x         |             |
| 26  | 4       | 0        | + (f)      | No                | 100/2 n         |             |
| 27  | 24      | 0        | + (f)      | No                | 100/1 n         |             |
| 28  | 60      | 60       | -          | No                | 100/0 n         |             |
| 29  | 48      | 1        | +          | No                | 100/0 n         |             |
| 30  | 48      | 0        | + (f)      | Left              | 100/2 x         |             |
| 31  | 12      | 0        | + (f)      | Right             | 100/2 x         |             |
| 32  | 24      | 0        | + (f)      | Right             | 90/2 x          |             |
| 33  | 12      | 0        | + (f)      | No                | 100/1 x         |             |
| 34  | 12      | 0        | + (f)      | Left              | 100/0 x         |             |
| 35  | 12      | 4        | +          | Left              | 100/0 +         |             |
| 36  | 48      | 0        | + (f)      | Right             | 100/1 +         |             |
| 37  | 24      | 0        | + (f)      | Right             | 100/1 x         |             |
| 38  | 48      | 4        | +          | Right             | 90/3 +          |             |
| 39  | 5       | 5        | -          | No                | 100/1 n         |             |
| 40  | 4       | 0        | + (f)      | Right             | 100/0 +         |             |
| 41  | 12      | 0        | + (f)      | Right             | 100/1 x         |             |
| 42  | 48      | 0        | + (f)      | Left              | 35/4 x          |             |
| 43  | 12      | 12       | -          | Left              | 100/2 x         |             |
| 44  | 48      | 12       | +          | Right             | 100/2 x         |             |
| 45  | 72      | 0        | + (f)      | Left              | 100/2 x         |             |
| 46  | 60      | 3        | +          | Right             | 100/3 x         |             |

pre SAH/post SAH: Episodes per year fulfilling the criteria of a migraine headache attack (isolated aura not included) before bleeding, Comparison pre vs. post: +: Significant reduction (<50%) / +: Complete disappearance / -: No significant reduction, Trepanation/Side: Side of trepanation if performed, Outcome: BI: Barthel index / mRS: modified Rankin scale, Correlation: +: Side of Pain and Trepanation equal, significant reduction of migraine / -: Side of Pain and Trepanation equal, NO significant reduction of migraine / O: Side of Pain and Trepanation NOT equal / x: No dominant pain side / n: No trepanation.
In addition, the higher proportion of patients with a higher Hunt and Hess grade who have become symptom-free may be due to a limitation of their cognitive abilities. Nonetheless, the results seem worth further discussion and investigation. It would be especially interesting and could substantiate our findings to observe and compare the course of preexisting migraines in non-SAH patients who had a craniotomy performed for other reasons. Unfortunately, we did not find such data in the literature.

CONCLUSION

Our data suggest that transection of the dura mater with the MMA and accompanying trigeminal branches may improve substantial migraine headache and not the elimination of the aneurysm alone. Further options of treatment should depend on future results of observational studies in patients with preexisting migraines who underwent a craniotomy.

DATA AVAILABILITY STATEMENT

The datasets presented in this article are not readily available because the participants of this research did not agree for their complete datasets to be shared publicly. Requests to access the datasets should be directed to JV, jose.valdueza@segebergerkliniken.de.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Medical Association Schleswig-Holstein (Germany) AZ.020/12 (I) and Charité University Medicine Berlin (Germany) EA4/022/09. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

JV conceived of the presented idea. JV, VW, and JD further developed the theory and performed analysis. All authors collected data at the different locations, discussed the results and contributed to the final manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

The work was financially supported by grants of the ERA-NET NEURON Network of European Funding for Neuroscience Research EBio2 and Deutsche Forschungsgemeinschaft (DFG) DFG DR 323/10-1 to JD; FP7 no 602150 CENTER-TBI to JD and OS; DFG DR 323/5-1 to JD, JW, and OS; DFG WO 1704/1-1 to JW. There was no involvement of the funding sources regarding study design, data collection, analysis, interpretation, writing, or decision of publication.

ACKNOWLEDGMENTS

We acknowledge and thank Dr. Christoph Drenckhahn for connecting research teams and for his valuable contributions to our work.

REFERENCES

1. Goadsby PJ, Lipton RB, Ferrari MD. Migraine-current understanding and treatment. N Engl J Med. (2002) 346:257–70. doi: 10.1056/NEJMra010917
2. Shevel E. The extracranial vascular theory of migraine—a great story confirmed by the facts. Headache. (2011) 51:409–17. doi: 10.1111/j.1526-4610.2011.01844.x
3. Schoonman GG, van der Grond J, Kortmann C, van der Geest RJ, Terwindt GM, Ferrari MD. Migraine headache is not associated with cerebral or meningeal vasodilatation—a 3T magnetic resonance angiography study. Brain. (2008) 131(Pt 8):2192–200. doi: 10.1093/brain/awn094
4. Goadsby PJ. The vascular theory of migraine—a great story wrecked by the facts. Brain. (2009) 132(Pt 1):6–7. doi: 10.1093/brain/awn321
5. Rahmann A, Wienecke T, Hansen JM, Fahrenkrug J, Olesen J, Ashina M. Vasoactive intestinal peptide causes marked cephalic vasodilatation, but does not induce migraine. Cephalalgia. (2008) 28:226–36. doi: 10.1080/01480700701497.x
6. Jansen I, Uddman R, Ekman R, Olesen J, Ottosson A, Edvinsson L. Distribution and effects of neuropeptide Y, vasoactive intestinal peptide, substance P, and calcitonin gene-related peptide in human middle meningeal arteries: comparison with cerebral and temporal arteries. Peptides. (1992) 13:527–36. doi: 10.1016/0196-9781(92)90084-G
7. Asghar MS, Hansen AE, Kapijimanga T, van der Geest RJ, van der Koning P, Larsson HBW, et al. Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers. Neurology. (2010) 75:1520–6. doi: 10.1212/WNL.0b013e3181f9626a
8. Cumberbatch MJ, Williamson DJ, Mason GS, Hill RG, Hargreaves RJ. Dural vasodilatation causes a sensitization of rat caudal trigeminal neurones in vivo that is blocked by a 5-HT1B/1D agonist. Br J Pharmacol. (1999) 126:1478–86. doi: 10.1038/sj.bjp.0702444
9. Nagata E, Moriguchi H, Takizawa S, Horie T, Yanagimachi N, Takagi S. The Middle Meninal Artery during a Migraine Attack: 3T Magnetic Resonance Angiography Study. Intern Med. (2009) 48:2133–5. doi: 10.2169/internalmedicine.48.2565
10. Dickerson D. Surgical relief of the headache of migraine. J Nerv Ment Dis. (1933) 77:42–52. doi: 10.1097/01.mao.000020530-19330100-00004
11. Fan Z, Fan Z, Wang H. New surgical approach for migraine. Otol Neurotol. (2006) 27:713–5. doi: 10.1097/01.mao.0000226304.66822.6d
12. Lin N, Brouillard AM, Mokin M, Natarajan SK, Snyder KV, Levy EI, et al. Direct access to the middle meningeal artery for embolization of complex dural arteriovenous fistula: a hybrid treatment approach. J Neurointerv Surg. (2015) 7:e24. doi: 10.1136/neurintsurg-2014-011256
13. Ironside N, Nguyen C, Do Q, Ugilweneza R, Cheb CJ, Sieg EP, et al. Middle meningeal artery embolization for chronic subdural hematoma: a systematic review and meta-analysis. J Neurointerv Surg. (2021) 13:951–7. doi: 10.1136/neurintsurg-2021-017352
14. Catapano JS, Karahalios K, Srinivasan VM, Baranoski JF, Rutledge C, Cole TS, et al. Chronic headaches and middle meningeal artery embolization. J Neurointerv Surg. (2022) 14:301–3. doi: 10.1136/neurintsurg-2021-SNIS.77
15. Olesen J, Steiner TJ. The International classification of headache disorders, 2nd edn (ICDH-II). J Neurol Neurosurg Psychiatry. (2004) 75:808–11. doi: 10.1136/jnnp.2003.013286
16. Drenckhahn C, Brabetz C, Majoer S, Wiesenthal D, Woztik J, Dreier JP, et al. Criteria for the diagnosis of noninfectious and infectious complications after aneurysmal subarachnoid hemorrhage in DISCHARGE-1. Acta Neurochir Suppl. (2013) 115:153–9. doi: 10.1007/978-3-7091-1192-5_30
Hunt WE, Hess RM. Surgical risk as related to time of intervention in the repair of intracranial aneurysms. J Neurosurg. (1968) 28:14–20. doi: 10.3171/jns.1968.28.1.0014

Kistler JP, Crowell RM, Davis KR, Heros R, Ojemann RG, Zervas T, et al. The relation of cerebral vasospasm to the extent and location of subarachnoid blood visualized by CT scan: a prospective study. Neurology. (1983) 33:424–36. doi: 10.1212/WNL.33.4.424

Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. (2007) 47:170–80. doi: 10.1111/j.1526-4610.2006.00684.x

Speciali JG, Peres M, Bigal ME. Migraine treatment and placebo effect. Expert Rev Neurother. (2010) 10:413–9. doi: 10.1586/ern.10.8

Liu T, Yu C. Placebo analgesia, acupuncture and sham surgery. Evid Based Complement Altern Med. (2011) 2011:1–6. doi: 10.1093/ecam/nee030

Haanes KA, Edvinsson L. Expression and characterization of purinergic receptors in rat middle meningeal artery-potential role in migraine. PLoS ONE. (2014) 9:e108782. doi: 10.1371/journal.pone.0108782

Benemei S, Cortese F, Labastida-Ramírez A, Marchese F, Pellesi L, Romoli M, et al. Triptans and CGRP blockade - impact on the cranial vasculature. J Headache Pain. (2017) 18:103. doi: 10.1186/s10194-017-0811-5

Yu J, Guo Y, Xu B, Xu K. Clinical importance of the middle meningeal artery: a review of the literature. Int J Med Sci. (2016) 13:790–9. doi: 10.7150/ijms.16489

Reuter U, Weber JR, Gold L, ArnolG, Wolf T, Dreier J, et al. Perivascular nerves contribute to cortical spreading depression-associated hyperemia in rats. Am J Physiol. (1998) 274:H1979–87. doi: 10.1152/ajpheart.1998.274.6.H1979

Witvoet EH, Pelzer N, Terwindt GM, Rinkel GJE, Vlak MHM, Algra A, et al. Migraine prevalence in patients with unruptured intracranial aneurysms: a case-control study. Brain Behav. (2017) 7:e00662. doi: 10.1002/brb3.662

Lebedeva ER, Bussyina AV, Kołotvinov VS, Sakovich VP, Olesen J. Remission of migraine after clipping of saccular intracranial aneurysms. Acta Neurol Scand. (2015) 131:120–6. doi: 10.1111/ane.12292

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Valdueza, Dreier, Woitzik, Dohmen, Sakowitz, Platz, Leistner-Glaess and Witt. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.